Form 8-K - Current report:
SEC Accession No. 0001104659-24-099121
Filing Date
2024-09-12
Accepted
2024-09-12 08:01:12
Documents
15
Period of Report
2024-09-12
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tm2423851d1_8k.htm   iXBRL 8-K 26092
2 EXHIBIT 99.1 tm2423851d1_ex99-1.htm EX-99.1 16928
3 GRAPHIC tm2423851d1_ex99-1img001.jpg GRAPHIC 5809
  Complete submission text file 0001104659-24-099121.txt   230671

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vyne-20240912.xsd EX-101.SCH 3042
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20240912_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20240912_pre.xml EX-101.PRE 22377
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2423851d1_8k_htm.xml XML 3683
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 241293942
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)